Edition:
United Kingdom

People: Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.36USD
6:29pm BST
Change (% chg)

$-0.06 (-0.71%)
Prev Close
$8.42
Open
$8.39
Day's High
$8.47
Day's Low
$8.23
Volume
61,850
Avg. Vol
439,834
52-wk High
$15.47
52-wk Low
$6.00

Guggenhime, Andrew 

Mr. Andrew L. Guggenhime is Chief Financial Officer of the Company. He has served as our Chief Financial Officer since April 2014. Mr. Guggenhime also served as our Chief Operating Officer from April 2014 until May 2018. From September 2011 to April 2014, Mr. Guggenhime served as Chief Financial Officer for CardioDx, Inc., a molecular diagnostics life sciences company, and as a member of the CardioDx board of directors from April 2014 until July 2016. From September 2010 to April 2011, Mr. Guggenhime served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc., a biotechnology company acquired in April 2011 by Gilead. From December 2008 to June 2010, Mr. Guggenhime served as Senior Vice President and Chief Financial Officer for Facet Biotech Corporation, a biotechnology company acquired in April 2010 by Abbott Laboratories. Facet Biotech Corporation was spun off from PDL BioPharma, Inc., a biopharmaceutical company, at which Mr. Guggenhime served as Chief Financial Officer from April 2006 to December 2008. From October 2000 to March 2006, Mr. Guggenhime served as Senior Vice President and Chief Financial Officer for Neoforma, Inc., a provider of supply-chain management solutions for the healthcare industry, and from January to October 2000 he served as its Vice President, Corporate Development. Mr. Guggenhime began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He currently serves on the board of directors of Metacrine, Inc., a privately held biotechnology company. Mr. Guggenhime holds an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.A. in international politics and economics from Middlebury College.

Basic Compensation

Total Annual Compensation, USD 1,612,650
Restricted Stock Award, USD 747,375
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 2,360,030

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 60,000 1,649,400.00
Name Fiscal Year Total

Thomas Wiggans

4,371,180

Luis Pena

2,519,500

Andrew Guggenhime

2,360,030

Christopher Horan

2,358,110

Christopher Griffith

833,154

Lori Lyons-Williams

2,704,630
As Of  31 Dec 2018